Table 1.
Baseline demographics and results
| Patients(n=87) | Control (n=82) | P | |
|---|---|---|---|
| Age, years | 63 (23–97) | 46.3±11.3 | <0.001 |
| Gender, male, % | 63.6 | 52.8 | <0.001 |
| DM, % | 52.3 | 21.2 | <0.001 |
| History of HT,% | 68.1 | 23.5 | <0.001 |
| eGFR, | 27.9 (8.0–53.6) | 87±10.3 | <0.001 |
| Etiology of CKD | |||
| DM or HT,% | 69.3 | ||
| Others, % | 30.7 | ||
| Laboratory parameters | |||
| β–2µ, ng/mL | 5.2±1.9 | 2.3±0.4 | <0.001 |
| Glucose, mg/dL | 102 (68–311) | 93±17.5 | <0.001 |
| BUN, mg/dL | 3 (16-94) | 12.9±19 | <0.001 |
| U, acid, mg/dL | 7.0±1.4 | 5.1±1.2 | <0.001 |
| T protein, g/dL | 7.2±0.5 | 7.22±1.5 | ns |
| Alb, g/dL | 3.9 (3.3–4.7) | 4.5±0.28 | <0.001 |
| TG, mg/dL | 162.1 (72.5) | 131±100 | ns |
| LDL, mg/dL | 127.9 (42.7) | 131±40 | ns |
| HDL, mg/dL | 42 (23–105) | 49±11 | 0.01 |
| CRP, mg/dL | 3.9±4.1 | 2.7±1.1 | <0.001 |
| iPTH, pg/mL | 115 (2.0–570) | 46±15 | 0.03 |
| P, mg/dL | 3.8±0.5 | 3.6±0.5 | ns |
| Hgb, g/dL | 12.2±1.5 | 12.2±1.3 | ns |
| CaXP, mg2/dL2 | 36.0±6.4 | 29.3±11.2 | <0.001 |
| Medications used | |||
| CC-B, % | 58 | 0.8 | – |
| β-B, % | 37.5 | 1.1 | – |
| RAS-B, % | 60.2 | 2.1 | – |
| Th, % | 30.7 | 2.0 | – |
| α-B, % | 17.2 | – | – |
| EPO, % | 25.0 | – | – |
| ViD-R, % | 63.6 | – | – |
| ASA for CAD, % | 14.8 | 0.3 | – |
| Furosemide, % | 8 | – | – |
α-B - alpha blocker; β-B - beta blocker; ASA - acetylsalicylic acid; BUN - blood urea nitrogen; CAD - coronary artery disease; CaXP - calcium XPhosphor; CC-B - Ca++ channel blocker; CRP - C-reactive protein; CKD - chronic kidney disease; DM - diabetes mellitus; eGFR - estimated glomerular filtration rate; EPO - erythropoietin replacement; HDL - high density lipoprotein; Hgb - hemoglobin; HT - hypertension; iPTH - intact parathormone; LDL - low density lipoprotein; P - phosphor; RAS-B - renin angiotensin system blocker; Th - thiazide; ViD-R - vitamin D replacement; ns - not significant; mL/min/1.73 m2